Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Dems call out Coburn on food safety

This article was originally published in The Tan Sheet

Executive Summary

Democrats on the House Oversight and Investigations Subcommittee call on Sen. Tom Coburn, R-Okla., to remove his hold on S. 510, the food safety legislation pending in the Senate. Coburn is "holding food safety legislation hostage," said Henry Waxman, Energy and Commerce Committee chairman. Republicans are trying to prevent any legislation from passing, explained Rep. Edward Markey, D-Mass. Ranking Republican Michael Burgess, R-Texas, attempted to read a statement from Coburn indicating Senate Majority Leader Harry Reid is delaying S. 510 during a Sept. 22 hearing, but Waxman turned off Burgess' microphone. Also during the hearing, FDA Principal Deputy Commissioner Joshua Sharfstein urged Congress to pass the bill, saying it will "do a lot more than help make eggs safer.

You may also be interested in...



Shiseido Aims To Be World’s No. 1 ‘Skin Beauty’ Company By 2030

With makeup and lipstick sales down globally at a time of wide mask use, Shiseido is focused on skin health, planning launches to address sensitive skin needs and heightened demand for cleansing and protection effects. In August, the firm projected a 16% decline in net sales for full-year fiscal 2020.

EU Firsts Beckon For Olumiant In Dermatitis & Orfadin For AKU

The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.

Roche Bulks Up In NLRP3 With €380m Inflazome Buy

Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel